Exchange: PNK Industry: Medical Care Facilities
-6.75% $7.46
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 61.82 mill |
EPS: | -1.140 |
P/E: | -6.54 |
Earnings Date: | Apr 18, 2024 |
SharesOutstanding: | 8.29 mill |
Avg Daily Volume: | 0.0093 mill |
RATING 2024-03-28 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Strong Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -6.54 | sector: PE -11.58 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.77x |
Company: PE -6.54 | industry: PE 8.44 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.03 (-72.83%) $-5.43 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 7.04 - 7.88 ( +/- 5.60%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-22 | Portnoy Mark L. | Buy | 25 000 | Stock Option |
2023-12-22 | Mikulinsky Oleg | Buy | 10 000 | Stock Option |
2023-12-22 | Taymans Jill M | Buy | 10 000 | Stock Option |
2023-12-22 | Portnoy David | Buy | 50 000 | Stock Option |
2023-10-10 | Berger Harold D. | Buy | 5 300 | Stock Option |
INSIDER POWER |
---|
82.19 |
Last 100 transactions |
Buy: 2 158 485 | Sell: 773 682 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $7.46 (-6.75% ) |
Volume | 0.0380 mill |
Avg. Vol. | 0.0093 mill |
% of Avg. Vol | 407.87 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.